Corporate Profile

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. To fulfill that mission our world class team of cell therapy pioneers and experts is focused on the discovery, development and commercialization of the most innovative and promising cell therapies.

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. To fulfill that mission our world class team of cell therapy pioneers and experts is focused on the discovery, development and commercialization of the most innovative and promising cell therapies.

Investor News and Events

Press releases
Events and presentations
Analyst Coverage
Shareholder Newsletters

Stock Information

Stock Quote and Chart
Historical Price Lookup

Corporate Governance

Corporate Charters
Corporate Policies

Resources

Resources

Chimeric Therapeutics was founded in 2020 by Paul Hopper.

Chimeric Therapeutics Pty Limited

Chimeric Therapeutics trades on the ASX (Australian Stock Exchange).

Chimeric is traded under the stock symbol CHM.

The company’s initial public offering was on January 18, 2021.

The company’s fiscal year ends on June 30th.

Chimeric does not offer a direct purchase plan for investors. You may purchase Chimeric stock through a licensed securities broker.